Ardea Biosciences — Corporate Update (January 2012)
56 slides from Ardea Biosciences's corporate update, Jan 9, 2012
Slide 1: Ardea Biosciences Company Update
Exhibit 99.1 Ardea Biosciences Company Update January 9, 2012
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statementscontainedin this presentationregardingmatters that are not historical facts are “forward-looking statements”within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may d
Slide 3: Status of Development Programs
Status of Development Programs Preclinical Phase 1 Phase 2 Phase 3 NDA Lesinurad (RDEA594) Gout RDEA3170 Next Generation Gout URAT1 BAY 86-9766 MEKI + sorafenib for primary liver cancer (RDEA119) BAY 86-9766 MEKI + gemcitabine for advanced (RDEA119) pancreatic cancer 3
Slide 4: Hyperuricemia/Gout
HYPERURICEMIA/GOUT 4
Slide 5: Gout Unmet Medical Need: Severe Disease Is Not Infrequent
Gout Unmet Medical Need Severe Disease Is Not Infrequent Allopurinol does a very poor job of treating severe disease 1 Velocity of Tophi Reduction Combination Benzbromarone Allopurinol 0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 (Images are courtesy of Nicola Dalbeth) 1. Perez-Ruiz F, Arthritis Rheum 2002;47:35
Slide 6: Hyperuricemia/Gout
Hyperuricemia/Gout Gout is caused by abnormally elevated levels of serum uric acid (>6.8 mg/dL) Increasing incidence and severity in US: approximately 8 million patients – ~ 90% of patients are “under-excretors” of uric acid • Lesinurad increases urinary excretion of uric acid; returns excretion to
Slide 7: Important Transporters Found in Kidney Proximal Tubule Cells
Important Transporters Found in Kidney Proximal Tubule Cells Proximal Tubule Transporters Responsible for Uric Acid Balance: creatinine URAT1 –primary reabsorption transporter 1 OCT2 OAT4 –secondary reabsorption transporter, also responsible for diuretic-inducedhyperuricemia1,2 ABCG2- urate secretio
Slide 8: Why Allopurinol Only Works in 30-40% of Patients and the Addition of Lesinurad Works
Why Allopurinol Only Works in 30-40% of Patients and the Addition of Lesinurad Works in 80-90% Typical Gout XO-Inhibitor Lesinurad + XO-Inhibitor Long-term Patient Treated Patient Treated Patient Treated Patient 600-800 <400 <400 <400 mg/day mg/day mg/day mg/day 6 mg/dL <4 mg/dL 400 mg/day 200 mg/da
Slide 9: Combination Therapy Keeps Uric Acid Output in Normal Range (Study 110)
Combination Therapy Keeps Uric Acid Output in Normal Range (Study 110) Excretion of undissociated urinary urate was well below the threshold for concern 2 about nephrolithiasis as reported by Perez-Ruiz20( mg/dL) Mean (SE) undissociated 24h urine urate (mg/dL) Baseline Allopurinol Combination RDEA59
Slide 10: Xanthine Oxidase Inhibitors Work in a Minority of Patients
Xanthine Oxidase Inhibitors Work in a Minority of Patients ITT Response Rates (sUA <6 mg/dL) APEX FACT CONFIRMS* 28-week Study 52-week Study 28-week Study (N=643) (N=491) (N=2268) Allopurinol 32% 29% 38% Febuxostat 40 mg 39% 36% 42% Febuxostat 80 mg 48% 52% 60% *CONFIRMS included approximately 10% o
Slide 11: Majority of Patients Do Not Reach sUA Target on Urate Lowering Therapy
Majority of Patients Do Not Reach sUA Target of < 6 mg/dL on Urate Lowering Therapy (ULT) in Clinical Practice Allopurinol Febuxostat Mild Moderate Severe Mild Moderate Severe Total 73% 69% 61% 61% 70% 65% 68% sUA> 6mg/dL sUA< 27% 31% 39% 39% 30% 35% 32% 6mg/dL Source: BioTrends Chart Review 2010, n
Slide 12: Majority of Patients Are Still Having Flares in Clinical Practice
Majority of Patients (ULT Treated or Not) Are Still Having Flares in Clinical Practice Percent of patients that experienced gout flares in last 12 months ULT Treated Not Treated 59% 65% Had Gout Flares Had Gout Flares 41% 35% No Gout Flares No Gout Flares Source: BioTrends Chart Review 2010, n=1039
Slide 13: Continued Upward Trend in Uloric Scripts Demonstrates Unmet Demand
Given Its Limited Differentiation From Allopurinol, Continued Upward Trend in Uloric Scripts Demonstrates an Unmet Demand for New Oral Gout Medications Uloric Weekly TRx thru November 18, 2011 25,000 November 18, 2011 20,000 TRx – 18, 568 Run Rate - ~230 Million 15,000 10,000 5,000 0 27-Feb-09 7-Jun
Slide 14: Uloric DTC Has Significantly Increased Growth Rate of Allopurinol in United States
Uloric DTC has Significantly Increased Growth Rate of Allopurinol in United States Allopurinol Unit Volume through September 2011 80,000,000 75,000,000 70,000,000 65,000,000 60,000,000 55,000,000 50,000,000 Uloric Branded 45,000,000 DTC Starts (~Oct 2010) 40,000,000 Apr-07 Nov-07 Jun-08 Dec-08 Jul-0
Slide 15: New ACR Draft Guidelines Will Result in More Aggressive Treatment of Gout
New ACR Draft Guidelines Will Result in More Aggressive Treatment of Gout Combination oral ULT endorsed for broad case scenarios (URAT1 + XO only combo) – The guidelines provide strong support for the use of combination therapy and can be the cornerstone of promotional activities Goal of ULT is SUA
Slide 16: New ACR Draft Guidelines Will Result in More Aggressive Treatment (continued)
New ACR Draft Guidelines Will Result in More Aggressive Treatment of Gout (continued) Pharmacologic ULT can be started during an acute gout flare attack, providing that effective anti-inflammatory management has been achieved – Reduces the loss of patients that don’t return for ULT initiation many w
Slide 17: Draft Treatment Guidelines Gout Case Scenarios
Draft Treatment Guidelines Gout Case Scenarios Symptoms Tophus or tophi Frequency Case detected on Scenario physical exam No Infrequent Symptoms (1 attack/yr) 1 No Frequent Symptoms (2-6 attack/yr) 2 Intermittent No Very frequent Symptoms (>7 attack/yr) 3 Symptoms Yes Infrequent Symptoms (1 attack/y
Slide 18: Summary of Gout Management Options and Objectives in Case Scenarios 1-9
Summary of Gout Management Options and Objectives in Varying Disease Severity Case Scenarios 1-9 No Tophi 1 Tophus Intermittent Symptoms CTGA 1 2 3 4 5 6 7 8 9 Diet, alcohol, weight management, and co-morbidity and medication review + + + + + + + + + Targetserumuric acid shouldbe loweredsufficiently
Slide 19: Gout Market Breakdown (2010)
Gout Market Breakdown (2010) Diagnosed Increasing prevalence/aging Gout 8.3M 2 Improved Compliance population Growing evidence of CV risk Education, advertising (DTC) Gout Pts New treatment guidelines on ULT 2.6M3 90% Allopurinol Allopurinol Treated Responders 2.5M 59-68% Trx Refractory Allopurinol
Slide 20: Gout Market Breakdown (2012)
Gout Market Breakdown (2012) Diagnosed Increasing prevalence/aging Gout 2 population 8.3M Improved Compliance Education, advertising (DTC) Growing evidence of CV risk Gout Pts New treatment guidelines on ULT 3 3.1M 90% Allopurinol Allopurinol Treated Responders 3 3.0M 59-68% Trx Refractory Allopurin
Slide 21: Recap of Opportunity
Recap of OpportunityAlmost - Half of Patients Under Treatment are Still Having FlaresLower – sUA Reduces Flares Proportion of subjects requiring More than half of the approximately treatment for gout flare after 11 3.1M patients receiving treatment are months of ULT by average post - 1 baseline sUA
Slide 22: Study 203: Lesinurad Phase 2b Combination Study with Allopurinol
Study 203: Lesinurad Phase 2b Combination Study with Allopurinol in Allopurinol-Refractory Patients Population: – 208 gout patients with serum urate (sUA) 6 mg/dL while receiving a stable dose of allopurinol for at least 6 weeks Duration: – 4-week double-blind treatment period with doses escalated w
Slide 23: Study 203: Primary Endpoint - Mean Percent Change in Serum Urate at Week 4
Study 203: Primary Endpoint - Mean Percent Change in Serum Urate at Week 4 5 ITT Population 3 0 -5 -10 -15 -16 p<0.0001 -20 -22 -25 p<0.0001 -30 -30 p<0.0001 -35 Placebo + Allopurinol RDEA594 200mg + RDEA594 400mg + RDEA594 600mg + Allopurinol Allopurinol Allopurinol Baseline sUA = 6.7 6.4 6.9 7.3 (
Slide 24: Study 203: Percent of Patients with sUA < 6 mg/dL at Week 4
Study 203: Percent of Patients with sUA < 6 mg/dL at Week 4 – Intent to Treat Analysis* 100% 90% p<0.0001 80% p<0.0001 79% 70% 74% p<0.0001 60% 63% 50% 40% 30% 20% 25% 10% 0% Placebo + Allopurinol Lesinurad 200mg + Lesinurad 400mg + Lesinurad 600mg + Allopurinol Allopurinol Allopurinol (N = 72) (N =
Slide 25: Study 203: Percent of Patients with Serum Urate < 6 mg/dL at Last Visit
Study 203: Percent of Patients w/ Serum Urate < 6 mg/dL at Last Visit – LOCF Analysis* LOCF analysis used in febuxostat US package insert 100% 90% p<0.0001 80% p<0.0001 87% 70% p<0.0001 76% 60% 71% 50% 40% 30% 20% 28% 10% 0% Placebo + Allopurinol Lesinurad 200mg + Lesinurad 400mg + Lesinurad 600mg +
Slide 26: Study 203: Lesinurad Works Well in Patients Receiving Diuretics
Study 203: Lesinurad Works Well in Patients Receiving Diuretics, Likely Due to its Activity Against OAT4 Response Rates by Use of Diuretics No Diuretics Yes Diuretics 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Placebo + Allopurinol RDEA594 200mg + RDEA594 400mg + RDEA594 600mg + Allopurinol Allopur
Slide 27: Lesinurad Consistently Lowers sUA Across Renal Function Categories
Lesinurad Consistently Lowers sUA Across Renal Function Categories Study 203 Lesinurad Allopurinol Add-on 10 0 -10 -20 -30 -40 -50 Lesinurad Lesinurad Lesinurad Placebo 200 mg +Allo 400 mg+Allo 600 mg +Allo +Allo normal impaired (mild to moderate) 27
Slide 28: Incidence of the Most Frequent Adverse Events
Incidence of the Most Frequent Adverse Events* Allopurinol + Lesinurad Dose Group Allopurinol + Combined Pooled Adverse Events 200mg 400mg 600mg Lesinurad Placebo (N=46) (N=42) (N=48) (N=136) (N=72) n (%) n (%) n (%) n (%) n (%) Any Adverse Event 1 (2.2) 4 (9.5) 5 (10.4) 10 (7.4) 10 (13.9) Diarrhea
Slide 29: Study 203: Safety Continued
Study 203: Safety Continued No Serious Adverse Events (SAEs) in main study 5 discontinuations due to adverse events in main study: 2 combination patients (urticaria, elevated lipase) 1 allopurinol patient (hematuria) and 2 baseline patients on allopurinol + colchicine (QT prolongation, elevated CK)
Slide 30: Study 203 - Optional Blinded Extension Period
Study 203 -Optional Blinded Extension Period Optional - Lesinurad 600mg/ matched placebo + increased Allopurinol (in 100 mg increments) Lesinurad 600mg / matched placebo + Allopurinol Lesinurad 400mg / matched placebo + Allopurinol Lesinurad 200mg / matched placebo + Allopurinol Weeks 0 - 4 Weeks 5
Slide 31: Study 203: Patients Receiving Lesinurad Have 90% Response at 44 Weeks
Study 203: Patients Receiving Lesinurad 200 mg* or 400 mg* Have 90% Response at 44 Weeks 81% of lesinurad patients are < 5 mg/dL at Week 44 90% 55% 44 Lesinurad group does not include patients who were escalated to 600 mg at any time. LOCF imputation used through Week 28. Week 44 is observed cases (
Slide 32: Patients on Lesinurad 200mg Continue to Decline for 16 Weeks
Patients on Lesinurad 200mg Continue to Decline for 16 Weeks: 28% Reduction in SUA Mean Change in sUA for Patients Staying on Lesinurad 200 mg n= 22 21 18 19 19 20 19 19 13 12 Confidential
Slide 33: Study 203 Extension: Safety
Study 203 Extension: Safety ~40% higher drop-out rate on placebo than lesinurad, with ~3-times as many patients in the lesinurad arms completing 44 weeks of blinded extension; after 44 weeks most placebo patients are switched to lesinurad Consistently lower flare rates on lesinurad 200 mg than place
Slide 34: Lesinurad Study 111: Phase 1b Febuxostat and Lesinurad Dose Titration Study
Lesinurad Study 111 – Phase 1b Febuxostat and Lesinurad Dose Titration Study in Gout Patients Population: – 21 gout patients with hyperuricemia (sUA 8 mg/dL) • febuxostat 40 mg panel: 12 patients with median sUA of 9.2 mg/dL • febuxostat 80 mg panel: 9 patients with median sUA of 10.4 mg/dL Objectiv
Slide 35: RDEA594 Study 111 Mean sUA and Percent Change in sUA
RDEA594 Study 111Mean – sUA and Percent Change in sUA febuxostat+ febuxostat+ febuxostat+l febuxostat+l febuxostat lesinurad lesinurad febuxostat lesinurad lesinurad 400 mg 600 mg 400 mg 600 mg 12 0 10 -20 All combination values are All combination values are p<0.001 versus to p<0.001 compared to 8
Slide 36: Study 111: Combining Lesinurad and Febuxostat Produces Much Greater Responses
Study 111: Combining Lesinurad and Febuxostat Produces Much Greater Responses than Can Be Achieved with Highest Dose of Febuxostat < 6 mg/dL < 5 mg/dL < 4 mg/dL < 3 mg/dL 120% *** # ## # ## ### 100% ### 80% * ** # 60% * ** 40% 20% 0% FBX 40 mg FBX 40 mg + FBX 40 mg + FBX 80 mg FBX 80 mg + FBX 80 mg
Slide 37: Study 202 - Phase 2b Lesinurad Monotherapy - Design
Study 202 -Phase 2b Lesinurad Monotherapy -Design Population: – gout patients with hyperuricemia (serum uric acid 8 mg/dL) – total of 123 patients in 4 treatment arms Duration: – 8 wks: 2-wk run-in, 4-wk treatment, 2-wk follow-up: dose was titrated up weekly Endpoints: – Proportion of subjects with
Slide 38: Study 202 – Phase 2b Monotherapy Response Rates for Urate Reduction
Study 202 – Phase 2b Monotherapy Study Response Rates for Urate Reduction 70% P<0.0001 60% 60% 50% P=0.0001 40% 42% 30% 20% 10% 13% 0% 0% Placebo Lesinurad 200 mg Lesinurad 400 mg Lesinurad 600 mg n= 27 31 33 32 Plasma urate assay using direct LC-MS method of analysis. ITT population 38
Slide 39: Study 202 – Response Rates by Baseline Urate Levels
Study 202 – Response Rates for Plasma Urate Reduction by Baseline Urate Levels 80% P<0.0001 70% 60% P=0.0004 P=0.0095 50% Baseline sUA 40% sUA >10 mg/dL sUA < 10 mg/dL 30% 20% 10% 0% Placebo Lesinurad 200 mg Lesinurad 400 mg Lesinurad 600 mg n= 27 31 33 32 Plasma urate assay for response using direc
Slide 40: Lesinurad Consistently Lowers sUA Across Renal Function Categories
Lesinurad Consistently Lowers sUA Across Renal Function Categories 40
Slide 41: No Serious Adverse Events
Lesinurad Dose Group Adverse Events 200mg 400mg 600mg Placebo (N=31) (N=33) (N=32) (N=27) Any Adverse Event 7% 15% 16% 15% Diarrhea 3% 0 3% 4% Dyspepsia 0 6% 0 0 Headache 0 3% 3% 7% *Adverse events reported by at least 2 subjects that were considered at least possibly related to treatment No Serious
Slide 42: Lesinurad Phase 3 Program
Lesinurad Phase 3 Program Long-termAllopurinolSafetyTrial(LASSO) – open-label interventional study of allopurinol in gout patients otherwise eligible for our Phase 3 studies Combination Study of Lesinurad in Allopurinol Standard of Care Inadequate Responders (CLEAR #1)randomized, – placebo-controlle
Slide 43: Long-term Allopurinol Safety Study Evaluating Outcomes in Gout Patients (LASSO)
Long-term Allopurinol Safety Study Evaluating Outcomes in Gout Patients (LASSO - N. America & Global) Population: – Up to 2500 pts with hyperuricemia (sUA 8 mg/dL) at ~240 centers – As of December 31, 2011 the were ~140 sites enrolling and ~580 patients enrolled Design: – Provide therapy with allopu
Slide 44: Combination Study of Lesinurad in Allopurinol Inadequate Responders (CLEAR #1 & #2)
Combination Study of LEsinurad in Allopurinol Standard of CareInadequateResponders(CLEAR #1 & #2 ) Population: – Gout patients with sUA > 6.5 mg/dL on stable dose of allopurinol between 300 mg to 800 mg (200 mg acceptable for moderate renal impairment) 12 for weeks – 2 gout flares in preceding 12 mo
Slide 45: Combination Treatment Study in Tophaceous Gout (CRYSTAL - Global)
Combination TReatment StudY in Subjects with TophAeous Gout Using LesInurad and Febuxostat (CRYSTAL - Global) Population: – Gout patients with hyperuricemia (sUA dependent on previous therapy) and 1 measureable tophus – No exclusion for history of kidney stones – Prospective assessment of patients n
Slide 46: Lesinurad Monotherapy in Gout Subjects Intolerant to XO Inhibitors (LIGHT)
LesInurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors (LIGHT - Global) Population: – Gout patients with sUA 6.5 mg/dL with medical history in which XO therapy is contraindicated (e.g., hypersensitivity, intolerance, or toxicity) Endpoints: – Primary: Proportion of patients
Slide 47: RDEA3170
RDEA3170 47
Slide 48: Comparison Between Uricosuric Agents for Inhibition of Uric Acid Transport by URAT1
Comparison Between Uricosuric Agents for Inhibition of Uric Acid Transport by URAT1 48
Slide 49: 60% Sustained Reduction in sUA After a Single Dose of RDEA3170 40 mg
60% Sustained Reduction in sUA After a Single Dose of RDEA3170 40 mg 0 -10 -20 -30 -40 -50 -60 -70 -80 0 12 24 36 48 60 72 Time (hr) N=6, fasted state
Slide 50: Cancer
CANCER 50
Slide 51: The Age of Targeted Cancer Treatments
The Age of Targeted Cancer Treatments GF Herceptin, Erbitux RTK Tarceva Ras Proliferation BAY80-6946 PI3K Angiogenesis AKT Differentiation Raf Nexavar Apoptosis mTOR BAY86-9766 MEK (RDEA119) c-Myc Bcl-2 c-Jun Elk-1 PDE4 Mcl-1 cPLA2 ERK2 ERK2 MNK1/2 MAPKAPK1/3 51
Slide 52: RDEA119 is Potent, Highly Specific MEK Inhibitor
RDEA119 is Potent, Highly Specific MEK Inhibitor MEK1/2 Enzyme IC 50 17-50 nM Cellular pERK EC 50 2.5-8.7 nM* >100-fold selectivity in kinase panel of 205 enzymes at 10 µM** MEK1 & MEK2 MEK1 & MEK2 100 100 80 80 60 60 Ron 40 40 SRC 20 20 0 0 1 6 1 6 11 11 16 21 16 21 26 26 31 *Cell lines: Colo205, A
Slide 53: Synergy between RDEA119 and Sorafenib in Hepatoma Cancer Lines
Synergy between RDEA119 and Sorafenib in Hepatoma Cancer Lines Huh7, day 6 120 HepG2, day 6 100 80 60 40 20 0 control Sorafenib- RDEA119- RDEA119 control Sorafenib-3.5uM RDEA119 - RDEA119 3.5uM 0.1uM +Sorafenib 0.25uM +Sorafenib 53
Slide 54: Current Bayer Clinical Trials with BAY86-9766
Current Bayer Clinical Trials with BAY86-9766* A Phase 2 Trial of BAY86-9766 Plus Sorafenib as First Line Systemic Treatment for Hepatocellular Carcinoma (HCC) A Multi-center, Phase 1/2 Study of BAY86-9766 in Combination With Gemcitabine in Patients With Locally Advanced Inoperable or Metastatic Pan
Slide 55: MEK Inhibitor Program
MEKInhibitor Program MEK program licensed to Bayer HealthCare on April 27, 2009 – $35 million upfront license fee – $15 million milestone received January 2011 for initiation of Phase 2 study in primary liver cancer by Bayer (NCT01304177) – Bayer has also initiated a Phase 1/2 combination study with
Slide 56: Financial Position
Financial Position Summary Statement of Operations Nine Months Ended (In thousands, except per share data) September 30, 2011 Revenue $ 5,636 Operating expenses 61,460 Other income, net 17 NET LOSS $(55,807) NET LOSS PER SHARE $(2.11) Condensed Balance Sheet Data September 30, (In thousands) 2011 De